跳至主要内容
临床试验/NL-OMON42369
NL-OMON42369已完成不适用

Comparison of Supera and Absolute Pro stent systems for femoro-popliteal lesions; a feasibility study - SAP feasability study

Catharina-ziekenhuis0 个研究点目标入组 40 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
40

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • - PAD (ABI <0.90 and/or a decline of >0.15 after exercise test), Rutherford category 2, 3 or 4
  • - Significant stenoses (* 50%) and/or occlusions in the superficial femoral artery and/or popliteal artery (P1)
  • - Eligible for endovascular treatment according to international guidelines (with the expectation of stenting after PTA)
  • - Adequate inflow (<50% stenosis) either pre-existing or successfully re-established prior to target lesion treatment without complications (e.g. embolization, thrombotic event, perforation, etc.)
  • - Age * 18

排除标准

  • - Patients with PAD Rutherford category 5 and 6
  • - Contralateral lesions that require treatment within 30 days before or after the procedure
  • - Contra-indication for anticoagulant therapy
  • - Life expectancy < 1 year
  • - Known contrast allergy
  • - Pregnancy
  • - Unable to complete a questionnaire in the home language

研究者

相似试验